| pubmed-article:18616968 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18616968 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:18616968 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:18616968 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:18616968 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:18616968 | lifeskim:mentions | umls-concept:C0011306 | lld:lifeskim |
| pubmed-article:18616968 | lifeskim:mentions | umls-concept:C0079720 | lld:lifeskim |
| pubmed-article:18616968 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
| pubmed-article:18616968 | lifeskim:mentions | umls-concept:C2346689 | lld:lifeskim |
| pubmed-article:18616968 | lifeskim:mentions | umls-concept:C1304884 | lld:lifeskim |
| pubmed-article:18616968 | lifeskim:mentions | umls-concept:C1515926 | lld:lifeskim |
| pubmed-article:18616968 | pubmed:issue | 36 | lld:pubmed |
| pubmed-article:18616968 | pubmed:dateCreated | 2008-8-11 | lld:pubmed |
| pubmed-article:18616968 | pubmed:abstractText | We have previously established a cancer vaccine using autologous DCs, generated by in vitro stimulation with IL-4 and GM-CSF, and pulsed with six HLA-A*0201 binding wild-type p53 derived peptides. This vaccine was used in combination with low-dose interleukin-2 in a recently published clinical Phase II trial where 26 HLA-A2+ patients with progressive late-stage metastatic breast cancer (BC) were included. Almost 1/3rd of the patients obtained stable disease or minor regression during treatment with a positive correlation to tumour over-expression of p53. In the present study, we performed a comprehensive analysis of the effector stage of the p53-specific CD8+ T cells by the use of Dextramer Technology and multicolour FACS. Pre- and post-treatment blood samples from eight BC patients were analysed. Independent of clinical outcome p53-specific T cells were phenotypic distinctly antigen experienced (CD44high, CCR-7low and CD62Llow). Furthermore, fresh blood from 18 cancer patients included in the vaccination trial were prospectively examined for more general treatment associated quantitative and qualitative changes in T cell subpopulations. We found that the frequency of CD4+ CD25high regulatory T cells was almost doubled after only 4 weeks of weekly vaccination and low-dose IL-2. In addition, a decrease in the percentage of CD27highCCR-7high CD4/CD8 naïve T cells was measured particularly in patients with progressive disease during vaccination. Finally, prior to immunotherapy a higher percentage of both CD28 and CD27 positive CD8naïve/early effector memory T cells were present in chemotherapy-treated patients. | lld:pubmed |
| pubmed-article:18616968 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18616968 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18616968 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18616968 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18616968 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18616968 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18616968 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18616968 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18616968 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:18616968 | pubmed:issn | 0264-410X | lld:pubmed |
| pubmed-article:18616968 | pubmed:author | pubmed-author:ZoccaMai-Brit... | lld:pubmed |
| pubmed-article:18616968 | pubmed:author | pubmed-author:SvaneInge... | lld:pubmed |
| pubmed-article:18616968 | pubmed:author | pubmed-author:PedersenAnder... | lld:pubmed |
| pubmed-article:18616968 | pubmed:author | pubmed-author:NikolajsenKir... | lld:pubmed |
| pubmed-article:18616968 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18616968 | pubmed:day | 26 | lld:pubmed |
| pubmed-article:18616968 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:18616968 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18616968 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18616968 | pubmed:pagination | 4716-24 | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:meshHeading | pubmed-meshheading:18616968... | lld:pubmed |
| pubmed-article:18616968 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18616968 | pubmed:articleTitle | Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. | lld:pubmed |
| pubmed-article:18616968 | pubmed:affiliation | Department of Oncology, Center for Cancer Immune Therapy, Copenhagen University Hospital at Herlev, Denmark. inge.m.svane@dadlnet.dk | lld:pubmed |
| pubmed-article:18616968 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18616968 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18616968 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18616968 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18616968 | lld:pubmed |
